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ABSTRACT 
The antiproliferative effects of Py-Im polyamides have been evaluated in several cancer 
models. The work presented here focuses on prostate cancer and the application of Py-Im 
polyamides targeted to the sequence 5′-WGWWCW-3′, which is found in a subset of 
androgen response elements. We begin by exploring the effect of a Py-Im polyamide in the 
VCaP model, which overexpresses wildtype AR and is genomically unstable due to ERG 
overexpression caused by the TMPRSS2-ERG translocation. In this model, Py-Im polyamide 
treatment reduces ERG protein level and DNA fragmentation, and reduces VCaP xenograft 
growth. Transcriptomic analysis of Py-Im polyamide treated VCaP cells provides a novel 
potential mechanism of blockage of topoisomerase I and II activity by polyamides. We next 
evaluate the activity of a second generation Py-Im polyamide in two models of anti-
androgen resistant prostate cancers, and demonstrate growth inhibition in both cell culture 
and tumor models. Transcriptomic analysis of the model cell lines revealed suppression of 
androgen receptor signaling. Further, expression profiles are consistent with transcription 
inhibition in both cell samples and tumor samples. Finally, we examine the effect of a Py-
Im polyamide on the AR cistrome in prostate cancer cells. We find through ChIP-Seq analysis 
that loci differentially affected by Py-Im polyamide treatment are enriched for potential 
ARE half-sites consistent with the polyamide target site. In summary, we find that Py-Im 
polyamides interfere with several DNA dependent processes, similar to other DNA minor 
groove binders, and we show through AR cistromic analysis that Py-Im polyamides reduce 
AR occupancy in a pattern that is predicted by Py-Im polyamide pairing rules. 
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C h a p t e r  1  
 
Introduction 
 
1.1 Background and significance 
Advancements in medical research have significantly changed health care needs in the last 
century. In 1900, the top three causes of death in the United States were 1) pneumonia and 
influenza, 2) tuberculosis, and 3) diarrhea, enteritis, and ulceration of the intestines. (1) 
Improved living standards, along with medical advances, have greatly reduced the 
prevalence of these communicable diseases and increased global life expectancy. This, in 
turn, has led to an increase in diseases that typically affect elderly patients.  As of 2016, 
heart disease and cancer were the leading causes of death by a significant margin in both 
the 50-70+ year old population and overall (Fig 1.1 A).  For comparison, the leading causes 
of death in the 5-14 year old population are malaria and road accidents.  (2) 
As a result of this change in health care needs, significant efforts and resources have been 
invested into the study of the underlying causes of heart disease and cancer.  Cancer in 
particular has been found to have a myriad of molecular mechanisms contributing to its 
development, which can vary based on the tissue of origin. Among these, cancers of the 
breast, colon, and prostate are the most commonly diagnosed world-wide (Fig 1.1 B). (3)  
For many cancers, the standard of care involves the use of chemotherapeutic toxins, which 
are effective largely because highly proliferative cancer cells are more sensitive than 
healthy cells. The side effects of these treatments, however, do not spare normal cells, and 
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extensive DNA damage increases the risk of secondary cancer, particularly in pediatric 
cancers. (4, 5)  
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The most common histologies of breast and prostate cancer represent a type of disease 
where a single dysfunctioning protein drives progression. The estrogen receptor (ER) is a 
well-established marker for breast cancer; the first experiments connecting ER status to 
treatment response were conducted in the 1970s. (6) Today, ERα status is an important 
predictor of survival and it is known that ERα positive tumors are more likely to respond to 
anti-estrogen therapy. (7) Similarly, it has been known since the early 1940s that the 
progression of prostate cancer can be slowed by androgen deprivation. (8) Therefore, 
inhibition of the estrogen receptor in breast cancer and the androgen receptor in prostate 
cancer have been mainstays in the treatment of these diseases. 
1.2 Prostate cancer biology and treatment 
Prostate cancer is the one of the most commonly diagnosed cancers, and the second 
leading cause of cancer death in men, with an estimated 161,360 new cases and 26,730 
deaths in the United States in 2017. (9) Early diagnosis and treatment is often curative with 
a five year survival of 98.2%. (10) After peaking in 1993, the mortality rate of prostate cancer 
steadily declined through 2015, due to more widespread screening and advances in 
diagnostics and treatment options. (11) However, prostate cancer with distal metastasis, 
which accounts for 5% of all prostate cancer cases, only has a five year survival rate of 29%. 
(9) This precipitous drop in treatment outcome is largely due to the development of 
heterogeneous disease. (10) 
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The androgen receptor is a nuclear hormone receptor that is important in the development 
of sex characteristics and muscle development. (12, 13) AR is normally sequestered in the 
cytosol by heat shock proteins and is activated when dihydrotestosterone (DHT) binding to 
the AR ligand binding domain induces structural changes to the receptor. (Fig 1.2 A, adapted 
from (14–16). Upon release, AR homodimerizes and translocates to the nucleus, where it 
binds to specific sequences on the DNA known as androgen response elements (ARE) (Fig 
1.2 B+C). Subsequent recruitment of transcriptional machinery results in the activation of 
gene expression programs collectively referred to as AR signaling.  
Androgen receptor activity is key to the survival of approximately 80-90% of prostate 
cancers at diagnosis, and often persists through multiple rounds of treatment. (17–20) If 
the disease is caught at an early stage, surgery and localized radiation is often sufficient for 
treatment, however, distal metastatic disease requires systemic treatment. The current 
treatment strategy for metastatic prostate cancer utilizes a combination of drugs that 
antagonizes the activity of the androgen receptor, collectively called androgen deprivation 
therapy (ADT).  
As implied by the name, ADT functions by blocking AR signaling through the interference of 
DHT-AR interactions or by depleting physiological levels of DHT or its precursor 
testosterone. The classical ADT drugs leuprolide and bicalutamide function by shutting 
down approximately 90-95% of testosterone production in the pituitary gland and blocking 
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DHT-AR interactions, respectively. (21) Abiraterone, enzalutamide, and apalutamide have 
also been approved recently, and have the same goal of reducing AR signaling. (22–24)  
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1.3 Limitations of current treatments 
While initially effective, relapse is often the inevitable outcome of ADT due to genomic 
variability, preexisting or acquired, and presence of compensatory pathways as shown in 
figure 2. (16, 25, 26) One example of circumvention of ADT is the bypass of testosterone 
depletion by leuprolide. Leuprolide is a peptide GnRH analog that over activates the GnRH 
receptors in the pituitary gland and abolishes the pulsatile stimulations required for normal 
sex hormone production. (27) To overcome the depletion of ligand, cancer cells can develop 
endogenous production of DHT through the utilization of the CYP17A1 enzyme. Inhibitors 
of this enzyme such as abiraterone have been developed to inhibit this enzyme and can be 
used collectively with classical ADT to deplete DHT levels. (28)  
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Modifications to or amplification of AR can overcome the absence of ligand. (25, 26, 29–31) 
Classic anti-AR drugs, including bicalutamide, enzalutamide, and apalutamide, target the 
ligand binding domain of AR and prevent AR-DHT interaction. However, in certain 
conditions bicalutamide is a weak agonist of AR, and cancer cells can often compensate by 
overexpressing AR and regain sufficient signaling to continue survival. (32) Enzalutamide, a 
second generation anti-AR drug approved in 2012, was developed to supplement lost 
bicalutamide activity, but recent studies indicate that the clinically relevant F877L/T878A 
mutations to the ligand binding domain can also result in receptor agonism. (25) 
Apalutamide, approved in early 2018, is an enzalutamide analog with superior 
pharmacokinetics; however, the same mutations confers resistance to both drugs. (24, 33, 
34) Furthermore, expression of splice variants of AR lacking the ligand binding domain 
altogether renders most anti-AR treatment completely ineffective. (26) Interestingly, many 
patients have been found to possess AR splice variants prior to enzalutamide or abiraterone 
treatment. (35) 
In addition to changes to the AR axis that renders ADT in effective, compensatory signaling 
mechanisms can also maintain disease viability in the absence of AR signaling. Recently, the 
glucocorticoid receptor, another nuclear hormone receptor with a nearly identical DNA 
response element was found to replace a subset of AR driven transcription in xenografts 
and patients treated with enzalutamide. (16) Collectively, these and other mechanism that 
confers resistance to treatment makes metastatic prostate cancer an incurable disease. 
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Due to the necessity for DNA binding for the activation of AR signaling, one potential way 
to attenuate transcription programs that drive disease progression is to target the DNA and 
block protein-DNA interactions of nuclear hormone receptors and their respective response 
elements through the use of pyrrole-imidazole (Py-Im) polyamides.   
1.4 Py-Im polyamides as anticancer agents 
Py-Im polyamides are minor groove binding molecules with modular sequence specificity 
and binding to targeted DNA sites with affinities comparable to DNA binding proteins. (36, 
37) Upon binding to the minor groove, Py-Im polyamides cause a distortion to the local helix 
that is characterized by an expansion of the minor groove and a corresponding compression 
in the opposing major groove. (38, 39) These molecules have been shown to affect gene 
expression in inducible transcription systems, including those induced by AR and GR. (40, 
41) Additionally, polyamides are able interfere with DNA dependent processes like RNA 
polymerase II elongation, DNA polymerase replication, and topoisomerase activity. (38, 42) 
They have also been shown to activate p53 and induce apoptosis without genotoxicity, and 
to have demonstrated antitumor activity in prostate cancer cell lines and xenograft models 
with little toxicity to the host mice. (42, 43)  
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Minor groove sequence recognition is determined by the side by side pairing of N-
methylimidazole (Im) and N-methylpyrrole (Py) in the minor groove of DNA, which allows 
specific hydrogen bonding to DNA base pairs (Fig 1.4 A). (44–46) The sequence recognized 
is dependent on the arrangement of the Im and Py monomers in the hairpin structure: an 
Im/Py pair will recognize a G•C pair in the DNA, Py/Im will recognize C•G, and Py/Py will 
bind to either A•T or T•A as shown in Figure 4. (38, 44, 47)  The polyamides used in this 
thesis target the sequence 5’-WGWWCW-3’, which is found in a subset of response 
elements common to AR and GR. 
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1.5 Scope of this work 
The work presented here focuses on the use of Py-Im polyamides in treatment resistant 
prostate cancer models. Chapter 2 describes the application of a Py-Im polyamide targeted 
to the 5’-WGWWCW-3’ sequence found in the androgen response element to a model 
expressing both GR and AR splice variants in addition to high levels of AR. Chapter 3 details 
the characterization of a next generation, less toxic hairpin polyamide targeted to the same 
sequence in the enzalutamide resistant prostate cancer models VCaP and LREX`. In Chapter 
4, we further evaluate the in vivo targeting of androgen receptor binding in an additional 
treatment resistant prostate cancer model. Appendix A describes structural modifications 
made to hairpin polyamides to increase their solubility, and Appendix B details the testing 
of a single hairpin in many formulations.  
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C h a p t e r  2  
Tumor Repression of VCaP Xenografts by a Pyrrole-
Imidazole Polyamide 
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Abstract 
Pyrrole-imidazole (Py-Im) polyamides are high affinity DNA-binding small molecules that 
can inhibit protein-DNA interactions. In VCaP cells, a human prostate cancer cell line 
overexpressing both AR and the TMPRSS2-ERG gene fusion, an androgen response element 
(ARE)-targeted Py-Im polyamide significantly downregulates AR driven gene expression. 
Polyamide exposure to VCaP cells reduced proliferation without causing DNA damage. Py-
Im polyamide treatment also reduced tumor growth in a VCaP mouse xenograft model. In 
addition to the effects on AR regulated transcription, RNA-seq analysis revealed inhibition 
of topoisomerase-DNA binding as a potential mechanism that contributes to the antitumor 
effects of polyamides in cell culture and in xenografts. These studies support the 
therapeutic potential of Py-Im polyamides to target multiple aspects of transcriptional 
regulation in prostate cancers without genotoxic stress. 
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2.1 Introduction 
Pyrrole imidazole (Py-Im) polyamides are non-covalent, sequence specific DNA binders that 
can alter DNA architecture. (1, 2) Upon high affinity binding to the DNA minor groove, the 
molecules cause a 4 angstrom widening of the minor groove walls and a corresponding 
compression of the opposing major groove. (3, 4) Despite the relatively large molecular 
weight of Py-Im polyamides, these molecules are cell permeable and localize to the cell 
nucleus to affect endogenous gene expression.(5–10) Due to their modular sequence 
specificity, Py-Im polyamides can be synthesized to target DNA sequences of similar size to 
a protein-DNA interaction site and therefore used to antagonize gene expression driven by 
specific transcription factors. (7, 9–13) One such transcription factor that has been studied 
previously is the androgen receptor (AR). (9) 
The AR is a dihydrotestosterone (DHT) inducible nuclear hormone receptor whose 
transcriptional program has been implicated in the progression of prostate cancer. (14–16) 
Upon ligand induction, AR will homodimerize, translocate to the nucleus and bind to 
conserved sequences known as the androgen response element (ARE) to regulate 
transcription. (17) Each monomeric unit binds to a half site of the sequence 5’-TGTTCT-3’. 
(18) Polyamide 1 (Fig 2.1) was designed to target the sequence 5’-WGWWCW-3’ (W = A/T), 
found in a subset of ARE half-sites, and has been shown to prevent AR binding at select 
AREs and attenuate AR signaling. (9) 
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In addition to antagonizing AR signaling, polyamide 1 is also cytotoxic towards prostate 
cancer cells. (19) Experiments in mice have shown that polyamide 1 is bioavailable via 
several routes of administration, with a serum half-life of 5.2 hours. (20, 21) In xenograft 
experiments, polyamide 1 has been shown to be active towards LNCaP xenografts at doses 
of 1 mg/kg. (19) LNCaP, however, expresses a mutated androgen receptor, and as a result, 
may not be representative of the majority of human disease. (22) It would therefore be 
useful to evaluate the efficacy of 1 against other forms of prostate cancer. 
The VCaP human prostate cancer cell line expresses wild type AR and contains the 
TMPRSS2-ERG fusion. (23) Gene fusions between the TMPRSS2 5’-untranslated region and 
the ERG oncogene are found in approximately half of prostate cancer cases. (24) The fusion 
allows the AR regulated TMPRSS2 promoter to drive the expression of ERG, and 
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overexpression of ERG in patients has been linked with higher incidences of metastasis and 
poor disease prognosis. (25) In cell culture, ERG overexpression in immortalized prostate 
RPWE epithelial cells and in primary prostate epithelial cells (PrEC) has been shown to 
increase cellular invasiveness. (26) Due to these characteristics, the VCaP cell line presents 
an ideal model for the study of Py-Im polyamide activity towards this common subtype of 
prostate cancer. In this study, we evaluated the activity of the ARE targeted polyamide 1 in 
VCaP cells. 
2.2 Materials and Methods 
Synthesis and quantitation of Py-Im polyamide 1 
Chemicals were obtained from Sigma Aldrich or Fisher Scientific unless otherwise noted. 
Synthesis was performed using previously reported procedures as indicated. (7, 27) Briefly, 
polyamides were synthesized by microwave-assisted solid phase synthesis on Kaiser oxime 
resin (Nova Biochem) (27) and then cleaved from the resin with neat 3,3’-diamino-N-
methyldipropylamine. The triamine-conjugated polyamides were purified by reverse phase 
HPLC and subsequently modified at the C-terminus with isophthalic acid (IPA) or 
fluorescein-5-isothiocyanate (FITC isomer I, Invitrogen). (7) The amine substituents of the 
γ-aminobutyric acid (GABA) turn units of the polyamides were deprotected using neat 
trifluoroacetic acid. (28, 29) The final polyamide was purified by reverse phase HPLC, 
lyophilized to dryness, and stored at -20°C. The identity and purity of the final compounds 
were confirmed by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) 
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spectrometry and analytical HPLC. Chemical structures are represented in Fig 2.1 and Fig 
S2.1 Mass spectrometry characterization data are represented in Fig S2.2. 
Py-Im polyamides were dissolved in sterile dimethylsulfoxide (DMSO, ATCC) and 
quantitated by UV spectroscopy in either 4:1 0.1% TFA (aqueous):acetonitrile (ε(310nm) = 
69,500 M-1cm-1) or 9:1 water:DMSO (ε(310nm) = 107,100 M-1cm-1) as dictated by 
solubility. Polyamides were added to cell culture solutions at 1000x concentration to give 
0.1% DMSO solutions. 
Cell culture 
The VCaP cell line was obtained from the laboratories of Dr. Kenneth J. Pienta and Dr. Arul 
M. Chinnaiyan at the University of Michigan Department of Pathology, where the cell line 
was derived. (30) VCaP cells were received at passage 19 and cultured in Dulbecco’s 
modified eagle medium (DMEM, Gibco 10313–039) with 4 mM glutamine (Invitrogen) and 
fetal bovine serum (FBS, Omega Scientific) on Corning CellBind flasks. All experiments were 
performed below passage 30. 
Cellular uptake studies 
For visualization of uptake using FITC-analog polyamides, VCaP cells were plated in 35-mm 
optical dishes (MatTek) at 7.5×104 cells per dish and allowed to adhere for 48 h. Media was 
then changed and cells were treated with 0.1% DMSO with polyamide for 24 or 48 h. Cells 
were imaged at the Caltech Beckman Imaging Center using a Zeiss LSM 5 Exciter inverted 
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laser scanning microscope equipped with a 63x oil immersion lens as previously described. 
(5) 
WST-1 proliferation assay 
VCaP cells were plated at 2x104 per well in 96-well plates coated with poly-L-lysine (BD 
BioCoat). After 24 h, an additional volume of medium containing vehicle or polyamide was 
added to each well. All medium was removed following polyamide incubation at the 
indicated time points and replaced with one volume of WST-1 reagent (Roche) in medium 
according to manufacturer protocol. After 4 h of incubation at 37°C, the absorbance was 
measured on a FlexStation3 plate reader (Molecule Devices). The value of A(450 nm)-A(630 
nm) of treated cells was referenced to vehicle treated cells. Non-linear regression analysis 
(Prism software, Graphpad) was performed to determine IC50 values. 
Gene expression analysis by quantitative RT-PCR (qPCR) 
For DHT induction experiments, VCaP cells were plated in 6-well plates coated with poly-L-
lysine (BD BioCoat) in charcoal-treated FBS containing media at a density of 31k/cm2 (3x105 
cells per well). The cells were allowed to adhere for 24 h and then dosed with 0.1% DMSO 
with or without polyamide 1 for 72 h followed by the addition of 0.01% ethanol in PBS with 
or without DHT (1 nM final concentration). Cells were harvested after additional 24 h 
incubation. Cells treated with etoposide and camptothecin (Sigma) were co-treated with 
DHT (1 nM) and harvested after a 16 h incubation. For native expression experiments, VCaP 
cells were plated as above but using standard FBS media and harvested after 72 h of 
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treatment. For all experiments, the mRNA was extracted using the QIAGEN RNeasy mini kit 
following the standard purification protocol. Samples were submitted to DNAse treatment 
using the TURBO DNA-free Kit (Ambion), and the mRNA was reverse-transcribed by using 
the Transcriptor First Strand cDNA Synthesis Kit (Roche). Quantitative PCR was performed 
by using the FastStart Universal SYBR Green Master (Rox) (Roche) on an ABI 7300 Real Time 
PCR System. Gene expression was normalized against GUSB. Primers used are referenced 
in Fig S2.3. 
Immunoblot of ERG protein levels 
For assessment of ERG and beta-actin protein levels, 3x106 VCaP cells were plated in 10 cm 
diameter dishes with charcoal-treated FBS containing media for 24 h before treatment with 
0.1% DMSO vehicle with or without polyamide 1 for an additional 72 h. Ethanol (0.01%) in 
PBS with or without DHT (1 nM final concentration) was then added. After 24 h incubation, 
cells were lysed in TBS-Tx buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% 
Triton X100) containing fresh 1 mM phenylmethanesulfonylfluoride (PMSF) and protease 
inhibitors (Roche). The samples were quantified by Bradford assay, denatured by boiling in 
Laemmli buffer, and total protein was separated by SDS-PAGE. After transfer to the 
polyvinyl difluoride (PVDF) membrane (Bio-Rad) and blocking with Odyssey Blocking Buffer 
(LI-COR), primary antibodies were incubated overnight at 4°C. Rabbit monoclonal anti-ERG 
antibody (Epitomics 2805–1) and rabbit polyclonal anti-actin antibody (Sigma A2066) were 
used. Goat anti-rabbit near-IR conjugated secondary antibody (LI-COR) was added and the 
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bands were visualized on an Odyssey infrared imager (LI-COR). The experiment was 
conducted in duplicate and the data are representative of both trials. 
Single cell electrophoresis (COMET) assay 
VCaP cells (3x106 cells) were plated in 10 cm cell culture dishes and allowed to adhere for 
24 h before addition of DMSO vehicle or polyamide stock in DMSO. After 72 h incubation, 
cells were washed with warm PBS (37°C), gently scraped, and counted. Samples were 
centrifuged, resuspended at 1x105 cells/mL, and treated according to manufacturer 
protocol (Trevigen) for neutral electrophoresis. Slides were stained with SybrGreen 
(Trevigen) and imaged at the Caltech Beckman Imaging Center using a Zeiss LSM 5 Pascal 
inverted laser scanning microscope equipped with a 5x air objective lens. Overlayed 
fluorescence and bright field images were obtained using standard filter sets for 
fluorescein. Images were analyzed using Comet IV software (Perceptive Instruments Ltd) 
with 200–600 comets measured per sample. A random sampling of 200 comets per 
condition was used for two-way analysis of variance (ANOVA) analysis (Prism software, 
GraphPad) of three biological replicates. 
Xenograft assays 
Male severe combined immunodeficiency (SCID) mice (4–6 weeks old) were obtained from 
a breeding colony maintained by the University of Michigan. Tumors were induced by 
subcutaneous injection of 1x106 VCaP cells (10 mice per dose group) in 200 μL of Matrigel 
(BD Biosciences, Inc., San Jose, CA) above the right flank. Tumor growth was monitored by 
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caliper measurement until the tumor size reached 100 mm3 using the formula 0.56 x L x W2. 
Groups were randomized and all mice were treated subcutaneously with control (DMSO) 
or with polyamide 1 as reported (3 times per week, 10 total injections). Tumor growth was 
followed weekly by caliper measurements. Animal husbandry and daily care and medical 
supervision was provided by the staff of the Unit for Laboratory Animal Medicine (ULAM) 
under the guidance of supervisors who are certified as Animal Technologists by the 
American Association for Laboratory Animal Science (AALAS) at the University of Michigan. 
Animals were monitored twice daily by both the research team and the veterinary staff. 
Health was monitored by weight (twice weekly), food and water intake, and general 
assessment of animal activity, panting, and fur condition. The experiments were performed 
in accordance with the guidelines on the care and use of animals set by the University 
Committee for the Use and Care of Animals (UCUCA) of the University of Michigan, and all 
procedures in this study were specifically approved by the UCUCA (Protocol Number 3848). 
In all cases, appropriate measures were taken to minimize discomfort to animals. All 
injections or surgical procedures were performed using sterile technique with efforts made 
to minimize trauma to the animals. When necessary, animals were anesthetized with a 
mixture of 1.75% isofluorane/air. Following injections animals were closely monitored and 
any that appeared moribund were immediately euthanized by administration of 
anesthesia, followed by inhalation of carbon dioxide until breathing ceased. Death was then 
ensured through cervical dislocation. 
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RNA-seq analysis 
VCaP cells (1x106 cells) were plated in 20 cm cell culture dishes and allowed to adhere for 
72 h in DMEM containing 10% FBS and 4 mM glutamine. Polyamide 1 or 0.1% DMSO vehicle 
were then added in fresh media and allowed to incubate for 96 h. Total RNA was collected 
by trizol extraction. Library building and sequencing were performed at the Caltech Millard 
and Muriel Jacobs Genetics and Genomics Laboratory. Sequenced reads were mapped 
against the human genome (hg19) with Tophat2 using Ensembl GRCh37 gene annotations. 
(31) Exon alignment was performed with htseq-count and differential expression was 
determined with DESeq2. (32, 33) Genes with padj < 0.05 and |log2(fold change)| ≥ 1 were 
submitted for connectivity map analysis online at http://lincscloud.org. 
Topoisomerase inhibition assay 
Topoisomerase inhibition kits were purchased from Topogen (Port Orange, FL). For Top2 
relaxation assays, 540 ng Top2α-p170 fragment (16 units) was added to 250 ng supercoiled 
pHOT1 DNA in assay buffer (0.05 M Tris-HCl (pH 8), 0.15 M NaCl, 10 mM MgCl2, 0.5 mM 
dithiothreitol) plus 2 mM ATP with or without test compounds in a total volume of 20 μL. 
The DMSO concentration was standardized to 1% for all samples except the no-DMSO 
solvent controls. Reactions were incubated at 37°C for 30 min and then quenched with 2 
μL 10% sodium dodecyl sulfate solution. Samples were then extracted with chloroform: 
isoamyl alcohol 24:1, mixed with 2 μL 10x glycerol loading buffer and loaded onto 1% 
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agarose gels in tris-acetic acid-EDTA (TAE) buffer with or without 0.5 μg/mL ethidium 
bromide (EtBr). Gels run without EtBr were post-stained with SYBR-Gold (Invitrogen). 
For Top1 assays, 0.5 μL Top1 (5 units) was added to 250 ng supercoiled pHOT1 DNA in assay 
buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA) plus 2 μL reaction buffer (10 mM Tris-HCl (pH 
7.9), 1 mM EDTA, 0.15 M NaCl, 0.1% BSA, 0.1 mM spermidine, 5% glycerol) with or without 
test compounds in a total volume of 20 μL. The DMSO concentration was again 
standardized to 1% for all samples except the no-DMSO solvent controls. Reactions were 
incubated at 37°C for 30 min and then quenched with 4 μL stop buffer (0.125% bromphenol 
blue, 25% glycerol, 5% Sarkosyl). Samples were then loaded onto 1% agarose gels in tris-
acetic acid-EDTA (TAE) buffer with or without 0.5 μg/mL ethidium bromide (EtBr). Gels run 
without EtBr were post-stained with SYBR-Gold. 
2.3 Results 
Nuclear uptake and cytotoxicity of Py-Im polyamide 
To test the nuclear uptake potential of polyamide 1, a FITC-labeled derivative was prepared 
(1-FITC) and incubated with VCaP cells prior to imaging by confocal microscopy (Fig S2.1). 
Polyamide 1-FITC signal was observed in the nucleus and also showed significant 
membrane binding. The overall level of uptake in VCaP cells was found to be qualitatively 
less than that in LNCaP cells. (21) Next, polyamide 1 was evaluated for antiproliferation 
effects in VCaP cells using the WST-1 assay under conditions similar to the gene expression 
experiment. After a 96 h incubation with polyamide, an IC50 value of 6.5 ± 0.3 μM was 
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determined for polyamide 1 (Fig 2.2A). At 72 h, the IC50 value for polyamide 1 in VCaP cells 
was found to be over 30 μM (data not shown). For comparison, polyamide 1 has been found 
to have an IC50 of 7 ± 3 μM after 72 h incubation in LNCaP cells. (19) 
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Reduction of DNA damage in VCaP cells upon treatment with Py-Im polyamide 
The effect of polyamide 1 on the high level of extant DNA damage in VCaP cells was also 
investigated. After incubation with polyamide, VCaP cells were submitted to the neutral 
Comet assay, which allows visualization of double-strand breaks through single cell 
electrophoresis (Fig 2.2B). The percentage of DNA in the “tail” of the comets was then 
compared using two-way ANOVA statistical analysis (Fig S2.4). A significant reduction in 
DNA damage (p < 0.001) was observed with polyamide 1 over the vehicle control. 
ARE-targeted Py-Im polyamide downregulates AR-driven TMPRSS2-ERG expression 
Next the effect of polyamide 1 on AR signaling in ERG-positive cells was examined. Dosage 
concentrations were chosen based on previous reports of polyamide gene expression 
effects in LNCaP. (28, 34) In VCaP cells, polyamide 1 was found to reduce the DHT-induced 
expression of the TMPRSS2-ERG fusion as well as other AR target genes, including PSA and 
FKBP5 (Fig 2.2C). Corresponding decreased expression of ERG protein was confirmed by 
Western blot (Fig 2.2D). In the non-induced state, polyamide 1 was also found to reduce 
expression of several ERG influenced genes, including PLAT and MYC (Fig S2.5). 
Diminished growth in VCaP xenografts upon polyamide treatment 
We next moved from cell culture studies to investigations of polyamide 1 in a VCaP mouse 
xenograft tumor model. Xenograft experiments were conducted in male SCID mice bearing 
subcutaneous VCaP cell xenografts. Treatments were started after tumor sizes in each 
group of mice reached ~100 mm3 and were administered three times per week through 
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subcutaneous injection in DMSO vehicle for three weeks for a total of 10 injections. Dose-
dependent retardation of tumor growth was observed in mice treated with polyamide 1 
(Fig 2.3). After 5 weeks of monitoring, tumors treated with vehicle grew to approximately 
6-fold the initial volume of that group while tumors treated with polyamide 1 at 5.0 mg/kg 
grew to approximately 1.6-fold the initial volume of that cohort. 
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Genome wide expression analysis 
RNA-seq analysis was performed after 96 hours of polyamide treatment in order to assess 
gene expression changes after prolonged exposure and to identify potential mechanisms 
of polyamide induced toxicity. Differential expression analysis using DESeq2 showed that of 
the genes with padj < 0.05 and |log2(fold change)| ≥ 1, 342 were upregulated and 399 were 
downregulated upon polyamide treatment (Fig 2.4A). Connectivity map analysis of these 
genes returned several compounds known to be topoisomerase inhibitors (Fig 2.4B), 
suggesting that the polyamide may also be interfering with topoisomerase activity. Analysis 
of a previously published genome wide data set from LNCaP cells treated with polyamide 1 
shows similar results (Fig S2.6)[9]. 
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Inhibition of topoisomerases 1 and 2 
Topoisomerase inhibitors have been shown to attenuate AR signaling in multiple cell lines. 
(35, 36) Similar results are also seen in VCaP cells, where treatment with etoposide and 
camptothecin is able to reduce DHT induced expression of select AR regulated genes (Fig 
S2.7). Based on the Connectivity map results, we examined the inhibitory effects of 
polyamide 1 against topoisomerase 1 and 2 in vitro. Topoisomerase 1 (Topo1) functions by 
relieving DNA supercoils generated by transcription and replication and is a therapeutic 
target in cancer. (37) To determine if polyamide 1 inhibits Topo1 mediated DNA cleavage, 
we titrated polyamide 1 with supercoiled pHOT1 plasmid and measured conversion to open 
circular plasmid or relaxation upon addition of purified Topo1. A reduction in DNA 
relaxation indicates polyamide 1 was able to attenuate Topo1 mediated cleavage of DNA 
(Fig 2.5A). To differentiate between open circular and relaxed DNA, samples were also run 
on an EtBr gel. Unlike camptothecin (CMT), which traps the Topo1 cleavage complex and 
generates nicked open circular DNA, treatment with polyamide 1 did not prevent DNA re-
ligation. Topoisomerase II cleaves double stranded DNA in an ATP dependent manner and 
is essential for strand separation of tangled daughter chromosomes during replication. Like 
Topo1, Topo2 is targeted in cancer therapy. (38) Similar to results seen for Topo1, 
polyamide 1 was able to inhibit Topo2 cleavage of supercoiled pHOT1 plasmid in a 
concentration dependent manner (Fig 2.5B). Furthermore, samples were run with EtBr to 
allow unambiguous identification of linearized DNA, which allowed the identification of 
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Topo2 cleavage complex (Topo2cc) formation (Fig 2.5B, lanes 5 and 6). The lack of Topo2cc 
formation in polyamide 1 treated samples as compared to linearized DNA and etoposide-
treated samples is consistent with disruption of Topo2 binding. 
 
2.4 Discussion 
In this study, we evaluated the activity of an ARE targeted polyamide in VCaP human 
prostate cancer cells. Polyamide 1 has been previously shown to exhibit antitumor activity 
in cell culture and in xenografts of the androgen sensitive LNCaP cell line (19), but there are 
several important genotypic differences between these two cell lines. First, VCaP cells 
possess an amplified AR region, leading to higher levels of AR protein than LNCaP cells. (30, 
39, 40) Additionally, VCaP cells belong to a subtype of prostate cancer that possesses the 
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TMPRSS2:ERG fusion, resulting in the AR driven expression of ERG. (23) ERG, an oncogenic 
transcription factor, has been reported to increase double stranded DNA break formation 
in PrEC cells, while knockdown of ERG by siRNA in VCaP cells have been shown to decrease 
DNA breaks. (41) Studies have also shown that ERG overexpression increases cancer 
invasiveness and has been correlated to increased metastasis in the clinic. (25, 26) 
In VCaP cell culture experiments, polyamide 1 exhibited antiproliferative activity and 
attenuated the DHT induced expression of select AR driven genes including TMPRSS2:ERG. 
Furthermore, in this cell line with high genomic instability due to ERG overexpression, 
treatment with polyamide 1 repressed the high level of DNA fragmentation found in the 
basal state, which may be attributed to diminished ERG protein. In vivo, VCaP xenografts 
treated with polyamide 1 exhibited reduced growth in a dosage dependent manner, 
demonstrating its potential as an anticancer therapeutic. 
To further examine the mechanism of action for polyamide 1, we conducted gene 
expression analysis of VCaP cells after exposure to polyamide 1 in the same time frame as 
the cytotoxic experiment. Connectivity map analysis of gene expression signatures from 
treated VCaP cells indicated overlap with expression profiles of several topoisomerase 
inhibitors. In vitro assays for inhibition of both Topo1 and Topo2 confirmed that polyamide 
1 is able to attenuate enzymatic activity of both enzymes. Similar results have been 
reported for other minor groove binders. (42–47) Furthermore, the lack of topoisomerase 
2 cleavage complex formation in the inhibition assays suggests polyamide 1 functions by 
34 
 
 
 
preventing protein-DNA interactions. This mechanism is in contrast to most drugs that 
target topoisomerases, which poison the enzymes. Drugs such as etoposide, doxorubicin, 
and camptothecin work by causing covalent adducts, which results in genotoxicity. (48) 
In addition to inhibition of Topo1 and Topo2, polyamide 1 has been reported to 
antagonize AR signaling, block RNA polymerase II elongation, and affect DNA replication by 
impeding helicase processivity. (19, 21, 49) These effects may be related, as inhibition of 
Topo1 has been shown to lead to RNA polymerase II and DNA polymerase stalling (50), and 
treatment of prostate cancer cells with topoisomerase inhibitors has been shown to 
attenuate AR signaling. (35, 36, 51, 52) Taken together, these data suggest that by virtue of 
targeting DNA and DNA:protein interactions, polyamide 1 may exhibit antiproliferative 
effects on cancer cells through polypharmacological mechanisms without inducing 
genotoxic stress. 
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A Pyrrole-Imidazole Polyamide is Active against 
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Abstract 
Effective treatment for enzalutamide-resistant prostate cancer is an unmet need. The LREX’ 
prostate cancer model is resistant to the antiandrogen enzalutamide via activation of an 
alternative nuclear hormone receptor (NHR), glucocorticoid receptor (GR), which has 
similar DNA binding specificity to the androgen receptor (AR).  Small molecules that target 
DNA to interfere with protein-DNA interactions may retain activity against enzalutamide-
resistant prostate cancers where ligand binding domain antagonists are ineffective. A 
pyrrole-imidazole (Py-Im) polyamide designed to bind the consensus androgen response 
element half-site has antitumor activity against hormone sensitive prostate cancer. In 
enzalutamide-resistant LREX’ cells this polyamide interferes with both androgen receptor 
and glucocorticoid receptor driven gene expression while enzalutamide interferes with only 
that of androgen receptor. Genomic analyses indicate immediate interference with the 
androgen receptor transcriptional pathway. Long-term treatment with the polyamide 
demonstrates a global decrease in RNA levels, consistent with inhibition of transcription. 
The polyamide is active against two enzalutamide-resistant xenografts with minimal 
toxicity. 
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3.1 Introduction 
Prostate cancer is the second leading cause of cancer death in American men with 26,000 
deaths annually (1), the majority from metastatic, castrate resistant prostate cancer 
(mCRPC), in which androgen deprivation therapy (ADT), which suppresses AR signaling, is 
ineffective. Enzalutamide, a potent AR-ligand binding domain (LBD) antagonist, is effective 
against mCRPC and is a current standard of care. (2) Unfortunately, de novo or acquired 
resistance to enzalutamide is common (3); overcoming this is an unmet need. 
Mechanisms of enzalutamide resistance include restoration of AR signaling through LBD 
mutations or expression of transcriptionally active splice variants lacking the LBD(4), bypass 
of AR signaling through alternative nuclear hormone receptors (NHR; ref. (5)), or 
development of complete independence from AR signaling. (6) Glucocorticoid receptor 
(GR) is an NHR with a sequence preference similar to AR. (7) After enzalutamide treatment, 
the LREX’ cell line highly expresses GR, which drives enzalutamide resistance by regulating 
gene expression significantly overlapping that of AR, suggesting prostate cancers co-opt GR 
to progress through AR antagonism. (5) Furthermore, GR expression in mCRPC associates 
with poor response to enzalutamide. (5) Therefore, interference with the NHR-DNA 
interface may overcome enzalutamide resistance.  
A pyrrole-imidazole (Py-Im) polyamide (ARE-1) is effective against hormone sensitive LNCaP 
xenografts with minimal host toxicity. (8) Py-Im polyamides are minor groove DNA binding 
small molecules with modular sequence specificity and high affinity. (9) Polyamide-DNA 
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binding induces widening of the minor groove and compression of the opposing major 
groove (10), interfering with transcription factor-DNA interactions and the transcriptional 
machinery. (11, 12) A polyamide targeted to the ARE might prevent AR and GR signaling, 
and transcription.   
We hypothesized that ARE-1 may be effective against enzalutamide-resistant prostate 
cancer.  We report ARE-1 efficacy against enzalutamide-resistant VCaP and LREX’ prostate 
cancer models in cell culture and xenografts.  Mechanistic studies reveal immediate 
interference with androgen-induced gene expression and reduced transcription after long-
term treatment. 
3.2 Materials and Methods 
Cell culture conditions and cytotoxicity assays. The LREX’ and LNCaP/AR cell lines were 
gifts from Charles Sawyers (Memorial Sloan Kettering Cancer Center, New York, NY) and 
were received in 2014 and 2007, respectively. The VCaP cell line was a gift from Kenneth 
Pienta (University of Michigan Medical School, Ann Arbor, MI) and was received in 2012. 
Cells were maintained as previously described (5, 8, 11–13) and were used within 10 
passages from thawing. Cells were validated to parental cell lines by STR profile at IDEXXX 
Bioresearch following experimentation and confirmed to be mycoplasma free. WST-1 assay 
(Roche) was used to measure cytotoxicity.  Long-term toxicity in VCaP cells was assayed by 
cell counting.   
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Confocal imaging.  Imaging was as described in ref. (8). Briefly, 2 µmol/L of ARE-1-FITC was 
added for 16 hours, washed with PBS, and imaged on a Zeiss LSM 5 Exciter.  
Gene expression analysis.  LNCaP/AR and LREX’ cells were cultured for 72 hours after 
plating in phenol-red free RPMI1640 (10% CT-FBS) in six well plates at 4 x 104 and 5 x 104 
cells/mL, respectively.  LNCaP/AR cells were treated with 10 µmol/L ARE-1, bicalutamide, 
or enzalutamide (Aurum Pharmatech) for an additional 48, 2, and 2 hours, respectively, 
prior to treatment with 1 nmol/L DHT or ethanol for 16 hours.  LREX’ cells were treated with 
10 µmol/L ARE-1 for 16hours prior to induction with 1 nmol/L DHT or 100 nmol/L 
dexamethasone for 8 hours. RNA extraction (RNEasy columns, Qiagen), cDNA generation 
(Transcriptor First Strand cDNA Kit, Roche), and qRT-PCR (SYBR Green Master Mix, Applied 
Biosystems, ABI7300 instrument) were as described in refs. (8, 11, 12). Expression was 
normalized to β-glucuronidase. 
RNA sequencing analysis.  LREX' cells were plated at 5 × 104 cells/mL in 10-cm2 dishes, 
treated with or without 10 μmol/L of ARE-1 in fresh media, incubated 16 hours, and induced 
with 1 nmol/L DHT for 8 hours. Tumor samples were homogenized mechanically.  Total RNA 
was Trizol extracted, sequenced (Illumina HiSeq2000), and mapped against the human 
genome (hg19) with Tophat2 using Ensembl GRCh37 gene annotations.  Human and mouse 
reads from tumor samples were parsed with BBSplit and unique reads were mapped. 
Htseq-count was used for exon alignment and DESeq2 for differential expression. Gene set 
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enrichment analysis (GSEA) was performed on genes with Padj < 0.05 and fold change ≥ 1.6 
for cell samples and Padj < 0.05 for tumor samples (SRP102746) 
Nascent RNA measurement.  LREX' cells were plated at 1 × 105 cells/mL in 96-well plates in 
RPMI1640 (20% FBS and 1 μmol/L enzalutamide), adhered for 24 hours, dosed with ARE-1, 
and incubated for 48 hours.  The Click-iT RNA Alexa Fluor 488 HCS kit was used for dye 
conjugation, and incorporation of 5-ethynyl uridine (5-EU) was measured on a FlexStation 
3 plate reader. 
Flow cytometry.  LREX’ cells were plated at 1 × 105 cells/mL in 175-cm2 flasks, adhered 24 
hours, incubated with 10 µmol/L ARE-1 24, 48, and 72 hours, then with 300 µmol/L 5-EU in 
fresh media.  Cells were detached by Accumax or Accutase, and Alexa Fluor 488 azide dye 
was conjugated.  Cells were passed through a 35µm mesh prior to flow, sorted on a 
FACSCalibur instrument (Becton Dickinson), and analyzed using FlowJo. 
Animal experiments. Animal experiments were performed at Caltech (Pasadena, CA) under 
IACUC approval. VCaP and LREX’ cells were engrafted as 1:1 mixtures of 3x106 cells in 
Matrigel (BD Biosciences) into the flanks of intact and castrated male SCID mice (Charles 
River Laboratories), respectively.  LREX’ engrafted mice received 10 mg/kg enzalutamide 
(oral gavage) daily. Once tumors were 100mm3 (0.5*l*w*w), ARE-1 was administered 
subcutaneously to opposing flanks in 20% DMSO:saline. For circulation studies, 4 C57BL6/J 
animals were injected subcutaneously with ARE-1 at 30mg/kg and blood collected retro-
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orbitally. Plasma concentrations of ARE-1 were analyzed by HPLC, AUC approximated by 
the linear trapezoidal method, as described. (8) 
Immunohistochemistry. Tumors were fixed in neutral-buffered formalin, paraffinized, 
sectioned, and stained as described. (12) Quantification of five random fields per slice was 
performed by ImmunoRatio.   
Statistical analysis. Cell culture experiments represent ≥3 independent biological 
replicates, except sequencing analyses, which were duplicates for cell culture and 
quadruplicates for tumor samples. For xenografts, animals were randomly assigned to 
groups. For circulation experiments, concentrations of ARE-1 were duplicate 
measurements. Measurements in cell culture, animal, and immunohistochemistry 
experiments were assessed by Student’s t-test. 
3.3 Results 
ARE-1 is more potent than enzalutamide against prostate cancer cell growth and is not 
rescued by GR activation  
ARE-1 (Fig. 3.1A) targets the sequence 5`-WGWWCW-3` (W=A or T), similar to the 
consensus half-site recognized by either AR or GR. Nuclear uptake in LNCaP/AR, LREX’, and 
VCAP cells was evaluated using fluorescent analog ARE-1-FITC (Supplementary Fig. S3.1). 
The LNCaP/AR cell line overexpresses full length AR, modeling castration resistance. (14) 
ARE-1 reduced proliferation of LNCaP/AR cells more than bicalutamide (Fig. 3.1B). The VCaP 
cell line overexpresses AR with modest GR expression, the activation of which reduces the 
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antiproliferative effects of enzalutamide. (5) ARE-1 reduced proliferation of both VCaP and 
LREX’ cells regardless of induction of AR signaling by 1 nmol/L DHT, induction of GR signaling 
by 100 nmol/L dexamethasone, or both (Fig. 3.1C-D). Long-term cell viability studies in VCaP 
cells show 10 µM ARE-1 is more potent than enzalutamide and insensitive to GR activation 
(Fig. 3.1D).  
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Py-Im polyamide attenuates androgen and glucocorticoid driven gene expression 
In androgen-depleted conditions, bicalutamide activates AR in the LNCaP/AR cell line. (14) 
Enzalutamide and ARE-1 demonstrate no agonist activity; ARE-1 reduced baseline 
expression of KLK3 (Fig. 3.2A).  In LREX’ cells, ARE-1 represses KLK3 and HOMER2 
expression, which are co-regulated by AR and GR (Fig. 3.2B).  While enzalutamide was more 
potent than ARE-1 in reducing DHT induced transcription, the opposite was observed with 
dexamethasone induction.  Furthermore, co-administration of enzalutamide and ARE-1 
was additive, suggesting ARE-1 may potentiate enzalutamide’s activity.  
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Global transcriptomic effects of Py-Im polyamide on enzalutamide sensitive and resistant 
CaP cells 
We performed RNA sequencing analysis on three treatment conditions in LREX’ cells: 
vehicle, DHT treatment, and co-treatment with ARE-1 and DHT, and two conditions in 
parental LNCaP cells: vehicle and ARE-1 treatment. GSEA of affected genes in LREX’ cells 
using the hallmark pathways in the Molecular Signatures Database revealed DHT treatment 
enriched for the AR signaling pathway as expected (Fig. 3.2C,  Supplementary Fig. S3.2; 
Supplementary Table S3.1). DHT-induced LREX’ cells treated with ARE-1 negatively enriched 
for the AR signaling pathway (NES -3.875; Fig. 3.2C, Supplementary Table S3.1), consistent 
with interference in AR driven gene expression by ARE-1. In addition, ARE-1 treatment 
negatively enriched for the UV DNA damage response pathway down (NES -4.310; Fig. 
3.2C). Similarly, ARE-1 treatment in LNCaP cells negatively enriched for the AR signaling 
pathway (NES -2.778) and the UV DNA damage response pathway down (NES -2.240) (Fig. 
3.2D,  Supplementary Table S3.1).  UV radiation induces DNA helical distortions through 
formation of pyrimidine dimers and 6-4 photoproducts, which arrest RNA polymerase II 
(RNAP2) during elongation, triggering degradation of RPB1. ARE-1 reduced nascent RNA in 
LREX’ cells as measured by 5-EU incorporation (Fig. 3.3), and we previously observed RPB1 
degradation after long-term treatment with ARE-1 and related polyamides. (8, 12)  This 
suggests that long-term treatment with ARE-1 reduces global transcription in LREX’ cells.  
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Suppression of enzalutamide resistant CRPC in vivo 
We further tested the efficacy of ARE-1 in VCaP xenografts, which exhibit modest response 
to 10 mg/kg enzalutamide treatment, and in mice engrafted with enzalutamide-resistant 
LREX’ cells. (5, 13) In VCaP xenografts, ARE-1 dose dependently reduced tumor growth by 
70% at 5 mg/kg compared with vehicle (Fig. 4A) without significant toxicity (Supplementary 
Fig. S3.3A). In castrated mice bearing LREX’ tumors, ARE-1 and enzalutamide cotreatment 
reduced growth by 80% compared with enzalutamide alone (Fig. 4B) without significant 
toxicity (Supplementary Fig. S3.3B). Enzalutamide was administered daily postengraftment 
at 10 mg/kg to maintain GR expression, which was confirmed by IHC. LNCaP tumors, which 
do not express GR, were used as controls (Fig. 3.4C).  Furthermore, LREX’ tumors treated 
with ARE-1 and enzalutamide showed reduced KLK3 expression (Supplementary Fig. S3.4C), 
elevated TUNEL, and reduced Ki67 staining compared to enzalutamide alone 
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(Supplementary Fig. S3.3D). GSEA of tumor expression profiles shows ARE-1 treatment 
elicits similar UV response signatures as seen in cell culture and represses ontologies 
associated with DNA binding-dependent transcription (Supplementary Tables S3.2 and 
S3.3).  Plasma concentration of ARE-1 from terminal blood samples collected from LREX’-
engrafted animals were compared with the plasma concentration in C57BL6/J animals 
treated with 30 mg/kg ARE-1; AUC was 25.9 and 189.9 µg*hr/mL, respectively 
(Supplementary Fig. S3.4). At 30 mg/kg mice experienced a 6% weight loss but recovered 
within 5 days without visible signs of distress (not shown).  
3.4 Discussion 
AR LBD mutations, expression of transcriptionally active splice variants lacking the LBD, co-
option of NHRs with similar DNA binding specificities, or loss of reliance on AR, may drive 
enzalutamide resistance. (3) Furthermore, different metastatic foci within a patient may 
resist enzalutamide through different mechanisms (15), suggesting a successful treatment 
strategy might use multiple therapeutics that overcome a different resistance mechanism, 
or alternatively, a single therapeutic capable of overcoming multiple mechanisms. 
Therapeutic targeting of the NHR-DNA interface may overcome most known enzalutamide 
resistance mechanisms.  
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The GR antagonist mifepristone added to ADT was previously tested in mCRPC patients and 
was not effective. (16) Trials for mCRPC patients combining enzalutamide with mifepristone 
are underway. Other NHRs may also be active in refractory prostate cancer. (3)  Notably, 
progesterone receptor inhibitors have entered clinical trials for mCRPC.  Therapeutics 
targeting the N-terminal domain (NTD) of AR, or that mediate degradation of AR, may 
overcome treatment resistance due to AR splice variants. The NTD inhibitor EPI-506 has 
entered clinical trials. (17) However this approach may not overcome resistance due to 
cooption of alternate NHRs. Others have reported small molecules that interfere with the 
AR DNA-binding domain. (18) The clinical utility of this approach is unknown.  
We report a Py-Im polyamide with activity against enzalutamide-resistant prostate cancer 
in cell and animal models. Polyamide ARE-1, targeted to the sequence 5’-WGWWCW-3’, 
which is similar to the ARE and GRE half-site, attenuates ligand-induced AR and GR 
transcriptional activity, is more potent than enzalutamide and bicalutamide in cell culture, 
and is active against enzalutamide-resistant xenografts. Long-term treatment of LREX’ cells 
with ARE-1 also decreases nascent RNA synthesis. In biophysical experiments, polyamides 
can halt RNAP2 elongation directly upstream of a polyamide binding site. (19) We 
hypothesize this stalling of RNAP2 promotes ubiquitination and degradation of RPB1, 
ultimately interfering with RNA synthesis, which may contribute to efficacy against 
treatment-refractory prostate cancer. Other molecules that interfere with RNA synthesis 
are proposed as potential drug candidates for prostate cancer. (13, 20) 
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Chapter 4 
Sequence specific suppression of androgen receptor-
DNA binding in vivo by a Py-Im polyamide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The text of this chapter is taken from a manuscript coauthored with Peter B. Dervan1.  
1 Division of Chemistry and Chemical Engineering,  
California Institute of Technology, Pasadena, CA 
 
Kurmis AA and Dervan PB. (2019) Sequence specific suppression of androgen receptor-DNA  
binding in vivo by a Py-Im polyamide. Nucleic Acids Research. Doi: 10.1093/nar/gkz153 
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Abstract 
The crucial role of androgen receptor in prostate cancer development is well documented, 
and its inhibition is a mainstay of prostate cancer treatment.  Here we analyze the 
perturbations to the androgen receptor cistrome caused by a minor groove binding 
molecule that is designed to target a sequence found in a subset of androgen response 
elements.  We find treatment with this pyrrole-imidazole polyamide exhibits sequence 
selectivity in its repression of androgen receptor binding in vivo. Differentially changed loci 
are enriched for sequences resembling ARE half-sites that match the Py-Im polyamide 
binding preferences determined in vitro. Comparatively, permutations of ARE half-site 
bearing single or double mismatches to the Py-Im polyamide binding sequence are not 
enriched. This study represents an indirect determination of Py-Im polyamide binding 
preference in vivo using an unbiased approach. 
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4.1 Introduction 
Transcription factors regulate cellular gene expression and the loss of this regulatory 
balance can lead to a myriad of genetic diseases including cancer.  The role of androgen 
receptor in prostate cancer is one of the most well characterized examples. Early work in 
1941 by Charles Huggins and Clarence Hodges showed that the progression of prostate 
cancer can be controlled by androgen deprivation through castration or hormonal therapy 
with estrogen. (1)  Later the discovery of the first anti-androgen, cyproterone acetate, 
allowed direct inhibition of androgen binding to the androgen receptor. (2) Since then, the 
androgen receptor has remained the primary target for systemic therapeutics for prostate 
cancer patients. (3, 4) In recent years, newer anti-androgens including enzalutamide and 
apalutamide have already been approved and others are in late-stage clinical development. 
(5–7)  
Metastatic prostate cancers treated with androgen suppressive therapy will ultimately 
progress to a disease state termed castration-resistant prostate cancer (CRPC). Second-line 
AR directed therapeutics, such as enzalutamide, are often effective against CRPC, but a 
second disease progression is almost inevitable. Two mechanisms that have been 
documented to confer resistance to second-line AR directed therapies are mutations to the 
AR C-terminal ligand binding domain and expression of AR splice variants lacking the ligand 
binding domain. (8–10)  Multiple approaches have been explored to overcome these 
resistance mechanisms, as reviewed recently by Jung and colleagues. (11) These include AR 
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transcription activation domain inhibitors such as EPI-506 and AR DNA binding domain 
inhibitors, such as pyrvinium pamoate. (11) In addition, our lab has previously reported the 
use of DNA binders to allosterically modulate the binding of androgen receptor at the 
protein-DNA interface. (12) We have shown this approach to be efficacious in several 
prostate cancer models, including anti-androgen resistant models. (13, 14)  
Py-Im polyamides are DNA minor groove binding molecules with modular sequence 
specificity that bind to target sites with affinities comparable to DNA binding proteins. (15, 
16) Minor groove sequence recognition is determined by the pairing of N-methylimidazole 
(Im) and N-methylpyrrole (Py); the target sequence of a particular polyamide is dependent 
on the location of the Im and Py monomers within the hairpin structure. (17) An Im/Py pair 
will recognize a G•C pair in the DNA, Py/Im will recognize C•G, and Py/Py will bind to either 
A•T or T•A. (18–20) Upon binding to the minor groove, Py-Im polyamides cause an 
expansion of the minor groove and a corresponding compression in the opposing major 
groove. (21) Py-Im polyamides have been shown to interfere with DNA dependent 
processes such as gene expression, RNA polymerase II elongation, DNA polymerase 
replication, and topoisomerase activity. (13, 22–24) They have also been shown to activate 
p53 and induce apoptosis without genotoxicity, and to have antitumor activity in prostate 
cancer cell lines and xenograft models. (13, 14, 23) ARE-1 is a Py-Im polyamide designed to 
target the sequence 5’-WGWWCW-3’, which is found in a subset of response elements 
common to AR and GR. 
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In this study, we evaluate the anti-proliferative effects of ARE-1 in the setting of 
enzalutamide resistant LNCaP-95 cells, and in the context of AR signaling.  We further 
examine the disruption pattern to the cistrome caused by ARE-1 treatment.  We find that 
at loci where AR binding is reduced by ARE-1 treatment, the consensus ARE motif bears 
closer resemblance to the ARE-1 target sequence, whereas the native consensus motif has 
more sequence degeneracy. 
4.2 Materials and Methods 
Cell culture 
The LNCaP-95 cell line was obtained from the laboratory of Dr. Jun Luo at Johns Hopkins 
School of Medicine. The cells were received at passage 3 and maintained in phenol red free 
RPMI 1640 (Gibco 11835-030) with 10% charcoal treated FBS. All experiments were 
performed below passage 20, and cells were validated to parental cell line and confirmed 
mycoplasma free by ATCC following experimentation.  
Cell uptake  
Cell uptake was confirmed by confocal imaging, as previously described. Briefly, LNCaP-95 
cells were plated in 35-mm optical dishes (MatTek) at 7.5×104 cells per dish and allowed to 
adhere for 24 h. Cells were treated with 2 µM ARE-1-FITC for 16 hours, washed with PBS, 
and imaged at the Caltech Biological Imaging Facility using a Zeiss LSM 710 inverted laser 
scanning confocal microscope equipped with a 63x oil immersion lens. 
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Cytotoxicity assay  
LNCaP-95 cells were plated at 7.5 x 103 per well in 96 well plates. Cells were allowed to 
adhere for 24 hours, and media was then replaced with fresh media containing vehicle or 
polyamide ARE-1. After 72 hours, an equivalent volume of CellTiter-Glo (CTG) reagent 
(Promega) was added to each well. Luminescence was allowed to stabilize for ten minutes 
at room temperature, according to manufacturer instructions, and then measured on a 
FlexStation3 plate reader (Molecular Devices). Background subtracted luminescence of 
polyamide treated cells was normalized to vehicle treated cells, and non-linear regression 
analysis (Prism software, Graphpad) was performed to determine IC50 value. 
Gene expression analysis by quantitative RT-PCR (qPCR) 
LNCaP-95 cells were cultured for 24 hours after plating in six well plates at 7.5 x 104 cells/mL.  
Cells were treated with 10 µM ARE-1 with 10 nM DHT or DMSO for 24 hours before harvest. 
RNA extraction (RNEasy columns, Qiagen), cDNA generation (ProtoScript II First Strand 
cDNA Synthesis Kit, NEB), and qRT-PCR (PowerUp SYBR Green Master Mix, Life 
Technologies, ABI7300 instrument) were done following manufacturer recommendations. 
Expression was normalized to β-glucuronidase. 
Bioavailability in new formulation 
All animal experiments were performed at the California Institute of Technology (Pasadena, 
CA) with prior IACUC approval. To evaluate a new formulation for polyamide delivery, ARE-
1 was injected at 10 mg/kg in a 1% polyvinylpyrrolidone K17 (PVP), 50 mM Tris, 0.9% saline 
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vehicle into the right flank of 6 C57BL/6J mice. Mice were anesthetized using isoflurane and 
blood collected retroorbitally at 30 min, 1h, 3h, 6h, 12h, and 24h after injection. Blood 
samples were centrifuged at 6000 rpm for 5 minutes to collect the serum, which was 
processed as previously published and analyzed by HPLC to determine polyamide 
concentration. (25) 9-aminoacridine was used as an internal standard. 
Xenograft assay 
Male SCID hairless outbred (SHO) mice (4-6 weeks old) were obtained from Charles River 
Laboratories. LNCAP-95 cells (3 x 106) were injected into the flanks of the mice as a 1:1 
mixture in Matrigel (BD Biosciences). Mice were monitored for the appearance of tumors 
and calipered twice weekly once tumors appeared. When tumors reached 100 mm3 (using 
0.5*l*w*w), animals were castrated by veterinary staff. Following surgery, animals were 
monitored daily for 3 days, and allowed to recover for 7-10 days prior to the start of 
treatment. After the recovery period, animals were randomly assigned to treated or vehicle 
groups, and injected 3 times per week with 2.5 mg/kg ARE-1 or vehicle (1% 
polyvinylpyrrolide K17 (PVP), 50 mM Tris, 0.9% saline) for 3 weeks. Tumor growth was 
monitored weekly by calipers, and growth compared to starting size. Animals were 
anesthetized with 2-5% isoflurane/air when necessary, and sterile technique was used for 
all procedures. Animal health was monitored daily by veterinary staff, and any animals 
exhibiting signs of distress were euthanized by administration of isoflurane followed by 
carbon dioxide.  
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Chromatin immunoprecipitation 
Genomic occupancy of full length AR was determined by chromatin immunoprecipitation 
(ChIP) with the PG21 antibody (Millipore). LNCAP-95 cells were plated at 20 million cells per 
plate in phenol red free RPMI 1640 supplemented with 10% CTFBS and allowed to adhere 
for 24 hours. The cells were treated with 10 µM ARE-1 with either 10 nM DHT or DMSO for 
24 hours. Formaldehyde crosslinking was performed and chromatin was 
immunoprecipitated by previously published methods. (12) DNA was then harvested by 
phenol chloroform extraction and purified using the Monarch PCR & DNA Cleanup kit (NEB). 
Quantitative PCR was used to validate enrichment at the KLK3 ARE I site (5′-
TGCATCCAGGGTGATCTAGT-3′ and 5′-ACCCAGAGCTGTGGAAGG-3′) compared to a negative 
internal locus (5′-TAGAAGGGGGATAGGGGAAC-3′ and 5′-CCAGAAAACTGGCTCCTTCTT-3′) 
prior to submission for sequencing. Each sample was immunoprecipitated as 3 technical 
replicates, which were combined for sequencing on an Illumina HiSeq2500. Biological 
replicates of each treatment condition were acquired. Input DNA (not immunoprecipitated) 
was also extracted and purified using the same methods and submitted for sequencing. 
ChIP-Seq analysis 
At least 29.7 million reads were sequenced for each sample. Reads were mapped to the 
human genome (hg19) using Bowtie2 v 2.2.3 and converted to BAM format with SAMtools. 
(26, 27) Peak calling was performed using the model-based analysis of ChIP-Seq (MACS2) 
program for each replicate. (28) Peaks from each replicate of each condition were 
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compared using IDR to determine a set of reproducible peaks, which was then submitted 
to MEME-ChIP (http://meme-suite.org/tools/meme-chip) for motif analysis. (29–31) Peaks 
selected by IDR were converted to bigWig format for viewing in the UCSC genome browser 
(http://genome.ucsc.edu).  
Differential analysis between treatment conditions was conducted using PePr. (32) PePr 
results were used for all further analysis. BEDtools was used for overlap analysis and peak 
annotation was performed using ChIPseeker. (33, 34) Differentially changed peaks were 
submitted to MEME-ChIP for motif finding as above. Based on the MEME-ChIP results, 
Homer was used to examine the density of specific motifs within peaks. (35) Data has been 
deposited and can be accessed in GEO (GSE125552).  
Thermal stabilization assay 
Melting temperature analysis of the DNA oligos 5′-TTGTAGAACACGTT-3′, 5′-
TTGTAGGACACGTT-3′, 5′-TTGTGGAACACGTT-3′, and 5′-TTGTGGGACACGTT-3′ in the 
presence of ARE-1 was conducted as previously described. (36) 
Statistical analysis 
All statistical analysis was performed in GraphPad Prism. Gene expression data was 
normalized to the DHT induced condition and ANOVA analysis was performed on three 
biological replicates using the Dunnett’s test for multiple comparisons. Statistical analysis 
of tumor percentage growth between vehicle and ARE-1 treated groups (N=11 per group) 
was performed using the unpaired t-test. All reported p-values are two-sided. 
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4.3 Results 
Nuclear uptake and cytotoxicity 
Py-Im polyamide ARE-1 has been previously shown to exhibit antiproliferative activity 
towards several models of prostate cancer including LNCaP, LNCaP-AR, VCaP, and LREX′. 
(14, 22) We further evaluate the activity of ARE-1 in LNCaP-95 cells, which derive their 
resistance from the expression of AR splice variants. (37) Nuclear localization of ARE-1 
(Figure 4.1A) was confirmed using a fluorescein analog, ARE-1-FITC (Figure S4.1), in LNCaP-
95 cells (Figure 4.1B).  Antiproliferative effect of ARE-1 towards LNCaP-95 cell growth was 
evaluated using the CTG assay and compared against the antiandrogen enzalutamide and 
pyrvinium pamoate (pyrvinium), a molecule that has been reported to bind to the AR DNA 
binding domain to prevent AR-DNA interactions. (38) Results from the assay show the 72hr 
growth inhibition IC50s for ARE-1, enzalutamide, and pyrvinium to be 20.1 µM, >30 µM, and 
44 nM, respectively.  A synergistic effect was observed when a subtoxic concentration of 
enzalutamide (5 µM) was combined with polyamide, and the IC50 was reduced to 3.4 µM.  
Changes to KLK3 gene expression was also evaluated in LNCaP-95 cells treated with ARE-1, 
enzalutamide, pyrvinium, and a combination of ARE-1 with pyrvinium or enzalutamide 
(Figure 4.1D).  After 24hr of treatment, the greatest reduction in KLK3 expression from 
treatment with a single agent came from ARE-1, and combining either additional agent with 
ARE-1 further reduced gene expression.  Based on these cell culture results, we further 
evaluated the antitumor effects of ARE-1 in LNCaP-95 xenografts using an optimized 
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formulation that increased the subcutaneous bioavailability when compared to the 
previously used DMSO/saline vehicle (Figure S4.2A).  Animals were engrafted with LNCaP-
95 cells and monitored until palpable tumors were observed.  Once tumors reached 
100mm3, the animals were castrated, allowed to recover for approximately one week, and 
then randomized before treatment (Figure 4.1E).  The animals were treated with either 
vehicle or 2.5mg/kg ARE-1 subcutaneously MWF for 3 weeks.  The vehicle treated group 
grew approximately 380%, while the ARE-1 treated group grew 225%, for a 40% reduction 
in tumor size in the polyamide treated mice (Figure 4.1F). Animal weight was measured at 
each injection and was not adversely affected (Figure S4.2B). 
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Genomic perturbation of androgen receptor occupancy 
The effects of Py-Im polyamide treatment on androgen receptor occupancy on chromatin 
have previously been explored by chromatin immunoprecipitation experiments. A related 
Py-Im polyamide, targeting the same sequence as ARE-1, has previously been shown to 
decrease occupancy of AR at the KLK3 promoter and enhancer in LNCaP cells. (12) In LNCaP-
95 cells, a similar reduction at the KLK3 promoter ARE I is seen after 24hr of cotreatment 
with ARE-1 and 10nM DHT (Figure S4.3A).  In this study, we explored the genomic effect 
ARE-1 treatment has on AR occupancy using ChIP-Seq analysis.  Sequencing results of 
biological duplicates of non-treated (NT), 10nM DHT treated (DHT), and 10nM DHT and 
10µM ARE-1 treated (DHT+ARE-1) showed approximately 30 million reads mapping for all 
samples (Figure S4.3B).  Sequencing reads were aligned to hg19 and select AR target genes 
are shown (Figure 4.2A-B).  Motif analysis by MEME discovered the forkhead binding motif 
in all samples, and the complete androgen response element (ARE) was discovered in the 
DHT and DHT + ARE-1 samples (Figure S4.3C).  Differential binding of DHT/NT and 
DHT/(DHT+ARE-1) was calculated using PePr.  Analysis revealed 16,015 peaks increased in 
DHT over non-treated (DHT/NT) and 6,343 differentially changed DHT/(DHT+ARE-1) peaks, 
of which 4,921 overlapped with DHT inducible peaks (Figure 4.2C).  Correlation of peak 
location to genomic regions, conducted by ChIPseeker, showed no difference between the 
DHT/NT, DHT/(DHT+ARE-1), and overlap peaks, suggesting that ARE-1 does not have a 
regional binding preference (Figure 4.2D).  Motif analysis of peaks unique to DHT/NT 
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revealed the canonical ARE where the first half-site is 5′-RGNACA-3′. In this motif, the first 
position is selective for A or G (R) and the third position is degenerate for any base (N) 
(Figure 4.2E).   Motif analysis of the overlapping peaks between DHT/NT and 
DHT/(DHT+ARE-1) also revealed a complete ARE; however, the first half-site has the 
sequence 5′-RGWACA-3′, where the third position shows selectivity for A or T (Figure 4.2E); 
additional motifs can be found in the supplemental information (Figure S4.4A).  Comparison 
of the letter probability matrix between the DHT/NT unique peaks and the overlapping 
peaks show more A character in the first position and reduced C and G character in the third 
position in the overlapping motif (Figure S4.4B). 
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Of the possible permutations of the first ARE half-site, ARE-1 is expected to have the 
strongest binding to the sequences 5′-AGWACA-3′.  Based on Py-Im polyamide pairing rules, 
ARE-1 is expected to have lower binding to the sequences 5′-GGWACA-3′ and 5′-AGGACA-
3′, which contain single base mismatches, and to have little binding to the sequence 5′-
GGGACA-3′, which contains two mismatches (Figure 4.3A). (17–20) DNA thermal stability 
experiments confirmed this trend and showed ARE-1 stabilized match sequences by ~9oC; 
single mismatches reduced thermal stability by ~2-4oC.  ARE-1 showed no significant 
thermal stabilization to a double mismatch sequence (Figure 4.3B).   
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The ARE half-site sequence 5′-RGNACA-3′ can be split into four sequences: 5′-AGWACA-3′, 
5′-GGWACA-3′, 5′-AGSACA-3′, and 5′-GGSACA-3′, where S represents G or C.  Density 
analysis of these 4 motifs revealed 5′-AGWACA-3′ to be significantly enriched around the 
peak center of DHT/NT and DHT/(DHT+ARE-1) overlap peaks compared to the other 
possible motifs. A lesser effect was found for the DHT/NT unique peaks (Figure 4.3 C-D). 
 
To confirm that the enrichment for 5′-AGWACA-3′ was only present in regions where AR 
peaks are affected by ARE-1, we examined common peaks between DHT/NT and 
(DHT+ARE-1)/NT samples (Figure 4.4A). Of the 7,998 overlapping peaks, 2,668 peaks had 
an absolute change of less than 1.5 fold.  Motif density analysis in these unchanged regions 
showed no enrichment of 5′-AGWACA-3′ (Figure 4.4B).  Comparatively, 5′-AGWACA-3′ was 
significantly enriched in 2,129 peaks showing greater than 2 fold change between DHT/NT 
and (DHT+ARE-1)/NT. 
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4.4 Discussion 
Py-Im polyamides have been shown to inhibit the signaling of oncogenic transcription 
factors and reduce their binding at select loci in ChIP experiments. (12, 39, 40) Genomic 
binding of Py-Im polyamides linked to DNA alkylators have also been examined. (41, 42) In 
this study, we elucidate the genome-wide effects of polyamide treatment on the androgen 
receptor on chromatin. Py-Im polyamide ARE-1 is a cell permeable molecule that exerts 
anti-proliferative effects towards several prostate cancer models, including the castration 
and enzalutamide resistant models LREX’ and now LNCaP-95. 
In this present study, we find that ARE-1 localizes to LNCaP-95 nucleus within 16 hrs of 
dosing, and is able to repress ligand-induced gene expression after 24 hrs of co-treatment 
with DHT.  In this time frame, our ChIP-Seq results show ARE-1 is able to repress ~30% of 
DHT inducible peaks.  Motif analysis of these AR peaks repressed by ARE-1, which is 
selective for the sequence 5′-WGWWCW-3′, indicates that these loci are enriched for 
canonical AREs with 5′-RGWACA-3′ as the first half-site compared to the common 5′-
RGNACA-3′ half-site.  Thus, the differential effects on AR-DNA binding events in vivo reflect 
the DNA target sequence binding preference of ARE-1 in vitro. These experiments provide 
evidence of the in vivo sequence selectivity of ARE-1, and provide a snapshot of how ARE-
1 modulates the AR cistrome. 
 
 
 
 
82 
 
 
 
References 
 
1. Huggins C and Hodges CV (1941) Studies on Prostatic Cancer. I. The Effect of Castration, 
of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of 
the Prostate. Cancer Res, 1, 293. 
2. Giorgi EP, Shirley IM, Grant JK and Stewart JC (1973) Androgen dynamics in vitro in the 
human prostate gland. Effect of cyproterone and cyproterone acetate. Biochem. J., 132, 
465–474. 
3. Heinlein CA and Chang C (2004) Androgen Receptor in Prostate Cancer. Endocrine 
Reviews, 25, 276–308. 
4. Sharifi N (2005) Androgen Deprivation Therapy for Prostate Cancer. JAMA, 294, 238. 
5. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo 
D, Kwon A, et al. (2009) Development of a Second-Generation Antiandrogen for Treatment 
of Advanced Prostate Cancer. Science, 324, 787–790. 
6. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, 
Cai L, et al. (2012) ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment. Cancer 
Research, 72, 1494–1503. 
7. Shore ND, Tammela TL, Massard C, Bono P, Aspegren J, Mustonen M and Fizazi K (2018) 
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and 
CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials. Eur Urol 
Focus, 4, 547–553. 
8. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG and Sawyers CL 
(2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med., 10, 33–
39. 
9. Dehm SM and Tindall DJ (2011) Alternatively spliced androgen receptor variants. Endocr. 
Relat. Cancer, 18, R183-196. 
10. Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke 
VG, et al. (2013) An F876L mutation in androgen receptor confers genetic and phenotypic 
resistance to MDV3100 (enzalutamide). Cancer Discov, 3, 1030–1043. 
11. Elshan NGRD, Rettig MB and Jung ME (2018) Molecules targeting the androgen receptor 
(AR) signaling axis beyond the AR-Ligand binding domain: ELSHAN ET AL. Medicinal Research 
Reviews, 10.1002/med.21548. 
12. Nickols NG and Dervan PB (2007) Suppression of androgen receptor-mediated gene 
expression by a sequence-specific DNA-binding polyamide. Proceedings of the National 
Academy of Sciences of the United States of America, 104, 10418–10423. 
13. Hargrove AE, Martinez TF, Hare AA, Kurmis AA, Phillips JW, Sud S, Pienta KJ and Dervan 
PB (2015) Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide. PLoS 
ONE, 10, e0143161. 
83 
 
 
 
14. Kurmis AA, Yang F, Welch TR, Nickols NG and Dervan PB (2017) A Pyrrole-Imidazole 
Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer. Cancer Research, 77, 
2207–2212. 
15. Trauger JW, Baird EE and Dervan PB (1996) Recognition of DNA by designed ligands at 
subnanomolar concentrations. Nature, 382, 559–561. 
16. Hsu CF, Phillips JW, Trauger JW, Farkas ME, Belitsky JM, Heckel A, Olenyuk BZ, Puckett 
JW, Wang CCC and Dervan PB (2007) Completion of a Programmable DNA-Binding Small 
Molecule Library. Tetrahedron, 63, 6146–6151. 
17. White S, Baird EE and Dervan PB (1997) On the pairing rules for recognition in the minor 
groove of DNA by pyrrole-imidazole polyamides. Chemistry & Biology, 4, 569–578. 
18. Kielkopf CL, White S, Szewczyk JW, Turner JM, Baird EE, Dervan PB and Rees DC (1998) 
A structural basis for recognition of A.T and T.A base pairs in the minor groove of B-DNA. 
Science, 282, 111–115. 
19. Kielkopf CL, Baird EE, Dervan PB and Rees DC (1998) Structural basis for G.C recognition 
in the DNA minor groove. Nat. Struct. Biol., 5, 104–109. 
20. Foister S, Marques MA, Doss RM and Dervan PB (2003) Shape selective recognition of 
T.A base pairs by hairpin polyamides containing N-terminal 3-methoxy (and 3-chloro) 
thiophene residues. Bioorg. Med. Chem., 11, 4333–4340. 
21. Chenoweth DM and Dervan PB (2010) Structural Basis for Cyclic Py-Im Polyamide 
Allosteric Inhibition of Nuclear Receptor Binding. Journal of the American Chemical Society, 
132, 14521–14529. 
22. Yang F, Nickols NG, Li BC, Szablowski JO, Hamilton SR, Meier JL, Wang C-M and Dervan 
PB (2013) Animal toxicity of hairpin pyrrole-imidazole polyamides varies with the turn unit. 
Journal of Medicinal Chemistry, 56, 7449–7457. 
23. Yang F, Nickols NG, Li BC, Marinov GK, Said JW and Dervan PB (2013) Antitumor activity 
of a pyrrole-imidazole polyamide. Proceedings of the National Academy of Sciences of the 
United States of America, 110, 1863–1868. 
24. Martinez TF, Phillips JW, Karanja KK, Polaczek P, Wang C-M, Li BC, Campbell JL and 
Dervan PB (2014) Replication stress by Py-Im polyamides induces a non-canonical ATR-
dependent checkpoint response. Nucleic Acids Res, 42, 11546–11559. 
25. Raskatov JA, Hargrove AE, So AY and Dervan PB (2012) Pharmacokinetics of Py-Im 
Polyamides Depend on Architecture: Cyclic versus Linear. Journal of the American Chemical 
Society, 134, 7995–7999. 
26. Langmead B, Trapnell C, Pop M and Salzberg SL (2009) Ultrafast and memory-efficient 
alignment of short DNA sequences to the human genome. Genome Biology, 10, R25. 
27. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin 
R and 1000 Genome Project Data Processing Subgroup (2009) The Sequence 
Alignment/Map format and SAMtools. Bioinformatics, 25, 2078–2079. 
84 
 
 
 
28. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers 
RM, Brown M, Li W, et al. (2008) Model-based analysis of ChIP-Seq (MACS). Genome Biol., 
9, R137. 
29. Li Q, Brown JB, Huang H and Bickel PJ (2011) Measuring reproducibility of high-
throughput experiments. The Annals of Applied Statistics, 5, 1752–1779. 
30. Machanick P and Bailey TL (2011) MEME-ChIP: motif analysis of large DNA datasets. 
Bioinformatics, 27, 1696–1697. 
31. Bailey TL, Boden M, Buske FA, Frith M, Grant CE, Clementi L, Ren J, Li WW and Noble 
WS (2009) MEME SUITE: tools for motif discovery and searching. Nucleic Acids Research, 
37, W202–W208. 
32. Zhang Y, Lin Y-H, Johnson TD, Rozek LS and Sartor MA (2014) PePr: a peak-calling 
prioritization pipeline to identify consistent or differential peaks from replicated ChIP-Seq 
data. Bioinformatics, 30, 2568–2575. 
33. Quinlan AR and Hall IM (2010) BEDTools: a flexible suite of utilities for comparing 
genomic features. Bioinformatics, 26, 841–842. 
34. Yu G, Wang L-G and He Q-Y (2015) ChIPseeker: an R/Bioconductor package for ChIP 
peak annotation, comparison and visualization. Bioinformatics, 31, 2382–2383. 
35. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H and 
Glass CK (2010) Simple combinations of lineage-determining transcription factors prime cis-
regulatory elements required for macrophage and B cell identities. Mol. Cell, 38, 576–589. 
36. Dose C, Farkas ME, Chenoweth DM and Dervan PB (2008) Next generation hairpin 
polyamides with (R)-3,4-diaminobutyric acid turn unit. J Am Chem Soc, 130, 6859–6866. 
37. Liu LL, Xie N, Sun S, Plymate S, Mostaghe ,E and Dong X (2014) Mechanisms of the 
androgen receptor splicing in prostate cancer cells. Oncogene, 33, 3140–3150. 
38. Jones JO, Bolton EC, Huang Y, Feau C, Guy RK, Yamamoto KR, Hann B and Diamond MI 
(2009) Non-competitive androgen receptor inhibition in vitro and in vivo. Proceedings of 
the National Academy of Sciences, 106, 7233–7238. 
39. Nickols NG, Jacobs CS, Farkas ME and Dervan PB (2007) Modulating hypoxia-inducible 
transcription by disrupting the HIF-1-DNA interface. ACS Chem Biol, 2, 561–571. 
40. Muzikar KA, Nickols NG and Dervan PB (2009) Repression of DNA-binding dependent 
glucocorticoid receptor-mediated gene expression. Proc Natl Acad Sci U S A, 106, 16598–
16603. 
41. Erwin GS, Grieshop MP, Bhimsaria D, Do TJ, Rodríguez-Martínez JA, Mehta C, Khanna K, 
Swanson SA, Stewart R, Thomson JA, et al. (2016) Synthetic genome readers target 
clustered binding sites across diverse chromatin states. Proc. Natl. Acad. Sci. U.S.A., 113, 
E7418–E7427. 
42. Chandran A, Syed J, Taylor RD, Kashiwazaki G, Sato S, Hashiya K, Bando T and Sugiyama 
H (2016) Deciphering the genomic targets of alkylating polyamide conjugates using high-
throughput sequencing. Nucleic Acids Research, 44, 4014–4024. 
 
85 
 
 
 
4.5 Supplemental material
86 
 
 
 
87 
 
 
 
88 
 
 
 
 
 
 
89 
 
 
 
Appendix A 
 
Influence of structure on aqueous solubility of 
hairpin Py-Im polyamides 
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A.1 Introduction 
 
The biological activity of Py-Im polyamides has been extensively explored in the context of 
enzymatic and cell culture experiments. (1–7) Py-Im polyamides have also shown efficacy 
against multiple xenograft models. (7–9) The subcutaneous administration of polyamides 
to animals, however, requires high levels of DMSO, typically 20% (10, 11) The goal of this 
study was to improve the aqueous solubility of a hairpin Py-Im polyamide by chemical 
modifications for use in future animal studies. Three Py-Im polyamides were selected for 
this purpose; their structures are shown in Figure A.1. Polyamides 1 and 2 contain a 2,2′-
(Ethylenedioxy)diethylamine (PEG) linker connecting the core to the C-terminal isophthalic 
acid (IPA), and polyamide 3 contains the 3,3′-Diamino-N-methyldipropylamine (triamine) 
linker.  
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A.2 Results 
Aqueous solubility 
The net charge of a molecule influences its aqueous solubility, and the pH of the solution 
can alter the charge. The standard hairpin polyamide carries a positive charge on the 
tertiary amine of the C-terminus and the adjacent IPA is negatively charged at physiological 
pH, leading to a net charge of 0, as shown in Figure A.2 A. Previously, it has been shown 
that replacing the triamine linker with a PEG linker results in similar biological activity. (12) 
This modification removes the positive charge, leaving the molecule with a net charge of -
1 at physiological pH (Fig A.2 B). The solubility of polyamides 1 and 3 was tested in water at 
three pH levels, and two additional solutions at basic pHs (Figure A.2 C and D), where the 
target concentration was 1 mM. Polyamide 1 was found to be completely insoluble at low 
pH, but at least 70% soluble at pH 7 and above, in water, Tris, and PBS. In contrast, 
polyamide 3 was most soluble in water at a pH of 12, with solubility significantly decreased 
in other conditions. While the PEG linker improves solubility, the DNA thermal stabilization 
of polyamide 1 was much lower than that of polyamide 3 (table A.1).  
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Gene expression 
Polyamide 3 has been shown to be toxic to multiple prostate cancer cell lines, both in cell 
culture and xenograft models, and to regulate expression of certain androgen receptor 
driven genes, including KLK3 (PSA) and FKBP5. (8, 7, 9) The increased aqueous solubility of 
polyamide 1 compared to polyamide 3 at physiological pH makes it an attractive candidate 
for further development. Polyamide 2 was also evaluated to investigate if the effect of the 
PEG linker applies to other polyamide structures; polyamides with aryl (R)-3,4-
diaminobutyric acid turns have been shown to be more biologically active than polyamides 
with (R)-2,4-diaminobutyric acid turns. (11) The effect of polyamides 1-3 on DHT induced 
gene expression was analyzed in LNCaP-AR cells. Cells were plated in charcoal treated FBS 
and allowed to adjust for 72 hours prior to treatment. All three polyamides reduced 
expression of both KLK3 and FKBP5 to below the DHT induced condition. Of the three, 
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polyamide 2 had the greatest effect, although only enzalutamide reduced expression of 
both genes to pre-induction levels. 
Cytotoxicity 
Cytotoxicity was assessed in a human prostate cancer cell line previously shown to be 
sensitive to polyamide 3 (Figure A.4 A). (9) Using the WST1 assay, polyamide 3 
demonstrates toxicity at 72 hours in LNCaP-AR cells, with an IC50 of 6.2 ± 2.6 µM. At the 
same time point, there is no apparent toxicity caused by polyamide 1. Viability was then 
investigated at 96 hours and found to be unchanged (Figure A.4 B). A cell counting 
experiment was then conducted to evaluate the cytotoxicity of polyamides 1 and 3 over a 
longer term. Cells were dosed with 10 µM polyamide 1 or 3, and counted at days 0, 3, and 
6. While polyamide 3 reduced growth by approximately 33% on day 3 and 60% on day 6, 
cells treated with polyamide 1 grew at the same rate as cells treated only with vehicle. 
(Figure A.4 C)  
Cytotoxicity of polyamide 1-3 was also assessed by WST1 in a human pancreatic cancer cell 
line, AsPC1. After 72 hours of treatment, polyamide 1 was found to actually increase cell 
viability at the highest dose of 30 µM. Polyamide 3 did not demonstrate significant toxicity, 
and an IC50 value could not be calculated. Polyamide 2, however, was extremely toxic, with 
an IC50 of 328 nM (Figure A.4 D).  
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In vivo toxicity 
Based on the gene expression and cytotoxicity results, polyamide 2 was chosen for further 
assessment in animal models and preliminary toxicity experiments were conducted in 
healthy C57Bl6/J mice. For toxicity studies, animals were injected subcutaneously with 
polyamide 2 at 0.3 or 1 mg/kg in a single dose or daily until adverse reactions were 
observed. Animals were monitored daily for signs of toxicity and weight loss. After a slight 
initial dip, both animals that received a single injection returned to their starting weights. 
97 
 
 
 
The animal receiving 1 mg/kg daily injections experienced a significant weight loss after only 
3 injections and was euthanized on day 4. The animal receiving daily 0.3 mg/kg injections 
was losing weight as well and injections were stopped after day 4. After a brief increase, 
the animal’s weight continued to decrease until the experiment was ended on day 9.  
 
A.3 Methods 
Aqueous solubility 
Aqueous solubility was determined according to previously published procedures. (10) 
Polyamides were dissolved in the minimum possible amount of DMSO and quantified by 
UV-vis. Polyamide stock and additional DMSO were added to test solvents (water at pH 3, 
7, or 12, 50 mM tris(hydroxymethyl)aminomethane at pH 8, or phosphate buffered saline 
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at pH 7.4) to reach 1 mM polyamide and 2% DMSO. Solutions were briefly vortexed, then 
sonicated for 20 minutes, incubated for 2 hours at room temperature, and centrifuged for 
20 minutes at 15,700 x g. To determine final concentration in solution, sample was analyzed 
by analytical HPLC and compared to a standard curve, using 9-aminoacridine as an internal 
standard. Data shown is the average of two replicates; error is SEM. 
Cytotoxicity 
Cytotoxicity was investigated in two human prostate cancer cell lines, LNCaP-AR and 22Rv1, 
and one human pancreatic cancer cell line (AsPC1). For WST1 assays, cells were plated at 4 
x 105, 1 x 106, and 5 x 105 per mL, respectively, allowed to adhere for 24 hours and then 
dosed with polyamide. Viability was measured at 72 hours for all cell lines, and also at 96 
hours for LNCaP-AR and 22Rv1. All medium was removed following polyamide incubation 
at the indicated time points and replaced with one volume of WST-1 reagent (Roche) in 
medium according to manufacturer instructions. After 2 h of incubation at 37°C, the 
absorbance was measured on a FlexStation3 plate reader (Molecule Devices). Absorbance 
was normalized to the nontreated condition. Non-linear regression analysis (Prism 
software, Graphpad) was performed to determine IC50 values. 
Cytotoxicity was also assessed by a cell counting assay in LNCaP-AR. Cells were plated in 6 
well plates 4 x 104 cells/mL, allowed to adhere 24 hours, and dosed with 10 µM polyamide 
1 or 3. Cells were harvested and counted at time of dosing (day 0) and at days 3 and 6 after 
dosing.  
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Gene expression 
LNCaP-AR cells were plated at 4 x 104 cells/mL in phenol-red free RPMI 1640 supplemented 
with 10% CTFBS and allowed to adjust for 72 hours prior to treatment. Cells were then co-
treated with ethanol (vehicle) or DHT (1 nM) and polyamide or enzalutamide at 10 µM 
(polyamides 1, 3, and enzalutamide) or 1 µM (polyamide 2). Cells were harvested 8 hours 
after treatment. RNA extraction (RNeasy, Qiagen), cDNA generation (Transcriptor First 
Strand cDNA Kit, Roche), and qRT-PCR (SYBR Green Master Mix, Applied Biosystems, 
ABI7300 instrument) were performed according to manufacturer instructions and 
expression was normalized to β–glucuronidase. 
Thermal stabilization assay 
Melting temperature analysis of the DNA oligo 5′-TTGCTGTTCTGCAAA-3′ in the presence of 
polyamides 1 and 3 was conducted as previously described. (13) 
In vivo toxicity 
All animal experiments were conducted with prior IACUC approval. For toxicity analysis, 
mice were injected subcutaneously with 0.3 mg/kg (n = 2) or 1 mg/kg (n = 2) polyamide 2 
in a 1% polyvinylpyrrolidone/50 mM tris vehicle. One animal per dose was injected only on 
day one, and one animal was injected daily (3 days for 1 mg/kg and 5 days for 0.3 mg/kg). 
Animal weight was monitored daily for 9 days, and any animal exhibiting signs of toxicity 
(including weight below 85% initial weight) was euthanized by CO2 inhalation. 
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A.4 Conclusions 
While the PEG linker afforded polyamide 1 greater solubility at physiological pH than the 
triamine containing polyamide 3, the DNA thermal stabilization was greatly compromised. 
A concurrent reduction in cytotoxicity was also observed, but this did not affect inhibition 
of DHT induced gene expression.  Polyamide 2 exhibited the most favorable profile in gene 
regulation and cytotoxicity, but was proven too toxic in animal studies to continue 
evaluation. 
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Appendix B 
Solubility and stability of hairpin polyamides in 
pharmaceutical excipients 
 
 
 
Py-Im polyamide 1 (Figure B.1) has shown efficacy in several prostate cancer xenograft 
studies. It has typically been administered in a 20% dimethylsulfoxide (DMSO)/saline 
solution. This appendix contains the results of several excipient screens conducted with the 
goal of finding a replacement for DMSO for use in animal studies.  
Three commercially available kits (Solubility and Stability, Solubility and Stability 2, and Slice 
pH, Hampton Research) were used to test a wide range of potential excipients. Polyamide 
1 was added to 96 well plates, lyophilized, and solutions from kits added for a final 
polyamide concentration of 50 µM. Plates were sonicated for 20 minutes, incubated for 
two hours at room temperature, and absorbance at 315 nm measured by a FlexStation3 
plate reader (Molecular Devices). Background at 700 nm was subtracted, and absorbance 
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from a control (solution only) plate was subtracted from each well.  Next, each well was 
normalized to the highest absorbance well on the same plate to determine relative 
solubility. Stability was determined by incubating the plates for 10 days at room 
temperature and analyzing high solubility wells for the presence of polyamide 1 by 
analytical HPLC. Results are shown in Tables B.1-3. Solutions with the greatest relative 
solubility were cross-referenced with the FDA Inactive Ingredients list to determine 
acceptable levels to be used for subcutaneous injection, and to exclude non-FDA approved 
excipients. Excipients scoring high in relative solubility and stability were tested for their 
ability to dissolve polyamide 1 at 1 mM, both alone and in combination with each other. A 
combination of 1% polyvinylpyrrolidone (PVP) and 0.6% tris(hydroxymethyl)aminomethane 
(Tris) achieved full solubility and this combination was chosen for animal experiments. 
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Animals were subcutaneously injected with 10 mg/kg polyamide 1 in 1% PVP/0.6% 
tris/saline and blood drawn retroorbitally at 1, 2, 4, 6, 12, and 24 hours. Plasma 
concentration was determined using analytical HPLC as described in chapter 4, and 
compared to a previous experiment where animals were injected with 30 mg/kg polyamide 
1 in 20% DMSO (Figure B.2). AUC/dose was significantly improved by the new formulation 
and it was subsequently adopted for the xenograft experiment described in Chapter 4.  
 
 
